Updated:
BetterLife Pharma Inc.
BetterLife Pharma Inc., led by CEO Ahmad Doroudian, develops psychedelic-based therapies for mental health, with a Phase 2a trial for BPL-003 underway.
BetterLife Pharma Inc.
BetterLife Pharma Inc. was founded to advance drug development programs leveraging psychedelic compounds, with a structural emphasis on intellectual property around routes of administration and formulations. The firm's pipeline includes BPL-003, a proprietary formulation of 5-MeO-DMT, currently in clinical trials for treatment-resistant depression. The strategy involves direct drug development rather than fund-based deployment, with capital allocated to preclinical and early-stage clinical research. Confirmed assets include BPL-003 and related patents. The firm operates primarily in North America, with clinical operations in Canada and the United States. Team size is not publicly disclosed. No additional offices or adjacent vehicles (e.g., foundations, SPVs) are confirmed. The firm's most recent operational milestone is the initiation of a Phase 2a clinical trial for BPL-003 in major depressive disorder, announced in early 2024 (per public statements). BetterLife Pharma's structural differentiator is its direct drug developer model — it operates as a public biotechnology entity rather than a passive investor, holding a focused pipeline of psychedelic assets and managing clinical trials internally, which is atypical for family offices that typically allocate capital to third-party funds or direct co-investments.
General information
Firm type
Family Office
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
Who runs investment decisions at BetterLife Pharma Inc.?
As a publicly traded biotech firm, strategic decisions are overseen by its board of directors and CEO Ahmad Doroudian. Day-to-day capital allocation is managed by the executive team, which includes leadership with pharmaceutical and financial backgrounds. No single investment committee is publicly named.
Does BetterLife Pharma operate as a family office or a biotech company?
The firm is structured as a public company (listed on the Canadian Securities Exchange under ticker BTLF) and conducts drug development, not capital allocation in the traditional family office sense. Its activities involve deploying capital into R&D and clinical trials for psychedelic compounds, which resembles an operating biotech rather than a passive investment vehicle.
What therapeutic areas does BetterLife Pharma target?
The firm focuses on mental health conditions, including treatment-resistant depression, anxiety disorders, and post-traumatic stress disorder (PTSD). Its lead compound, BPL-003, targets major depressive disorder. The pipeline also includes patent-protected formulations and devices for drug delivery.
What is BetterLife Pharma's known posture on co-investments alongside external GPs?
There is no public record of BetterLife Pharma engaging in co-investments with external general partners. The firm's model is direct drug development, not fund commitments or syndicated deals.
Where does BetterLife Pharma conduct its clinical operations?
Clinical trials are conducted in North America, primarily Canada and the United States. The company is headquartered in British Columbia, Canada, but regulatory filings indicate operations in Vancouver and Montreal.
How is BetterLife Pharma structured relative to other psychedelic biotech firms?
BetterLife Pharma is a vertically integrated developer with a proprietary formulation focus, differentiating it from firms that license compounds or operate as contract research organizations. The firm holds intellectual property around 5-MeO-DMT delivery methods, which it argues reduces competition.
Does BetterLife Pharma maintain philanthropic structures?
No philanthropic foundation or non-profit vehicle is publicly disclosed. The firm's activities are entirely commercial, targeting regulatory approval for its drug candidates.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: